Capital Fund Management S.A. Acquires 26,392 Shares of Sarepta Therapeutics, Inc. $SRPT

Key Points

• Capital Fund Management S.A. acquired an additional 26,392 shares of Sarepta Therapeutics, increasing its ownership by 15.2% to a total of 200,137 shares, valued at approximately $12.77 million.
• Sarepta Therapeutics reported a significant increase in quarterly revenue of 68.4%, reaching $611.09 million, and beat earnings estimates with an EPS of $2.02 compared to a consensus of $0.89.
• Institutional investors own 86.68% of Sarepta Therapeutics shares, with several major firms like Wellington Management and Farallon Capital increasing their stakes recently.

Capital Fund Management S.A. lifted its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 15.2% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 200,137 shares of the biotechnology company's stock after acquiring an additional 26,392 shares during the quarter. Capital Fund Management S.A. owned approximately 0.20% of Sarepta Therapeutics worth $12,773,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Farallon Capital Management LLC lifted its position in shares of Sarepta Therapeutics by 11.1% during the 4th quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company's stock valued at $348,368,000 after acquiring an additional 285,100 shares during the period. Wellington Management Group LLP raised its holdings in shares of Sarepta Therapeutics by 27.9% during the 1st quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company's stock worth $168,907,000 after buying an additional 577,848 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its holdings in Sarepta Therapeutics by 0.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,956,583 shares of the biotechnology company's stock worth $237,901,000 after purchasing an additional 10,343 shares in the last quarter. Alkeon Capital Management LLC increased its holdings in Sarepta Therapeutics by 34.7% in the 4th quarter. Alkeon Capital Management LLC now owns 853,845 shares of the biotechnology company's stock worth $103,819,000 after purchasing an additional 220,000 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in Sarepta Therapeutics by 22.6% in the 4th quarter. Northern Trust Corp now owns 803,511 shares of the biotechnology company's stock worth $97,699,000 after purchasing an additional 147,874 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Trading Up 2.0%

NASDAQ SRPT opened at $20.58 on Thursday. Sarepta Therapeutics, Inc. has a 1-year low of $10.41 and a 1-year high of $144.22. The company has a current ratio of 2.89, a quick ratio of 1.81 and a debt-to-equity ratio of 0.84. The stock has a 50-day moving average of $18.65 and a 200-day moving average of $52.02. The firm has a market cap of $2.01 billion, a PE ratio of -23.65 and a beta of 0.46.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, beating analysts' consensus estimates of $0.89 by $1.13. The business had revenue of $611.09 million during the quarter, compared to analyst estimates of $530.66 million. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.Sarepta Therapeutics's quarterly revenue was up 68.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.07 EPS. As a group, sell-side analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Wall Street Analyst Weigh In

SRPT has been the topic of a number of analyst reports. Leerink Partnrs lowered Sarepta Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, July 18th. Jefferies Financial Group cut their target price on Sarepta Therapeutics from $40.00 to $35.00 and set a "buy" rating on the stock in a research report on Thursday, July 24th. William Blair reiterated an "outperform" rating on shares of Sarepta Therapeutics in a report on Tuesday, July 29th. Sanford C. Bernstein initiated coverage on Sarepta Therapeutics in a research note on Tuesday, July 29th. They issued a "market perform" rating and a $13.00 price objective for the company. Finally, Wall Street Zen raised Sarepta Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. Eight investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and six have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $43.50.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.